Yeon Hee Hong1, Soo Jin Han2, Dayong Lee1, Seul Ki Kim1,3, Byung Chul Jee1,3
1Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea
2Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea
3Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
Tóm tắt
AbstractAimTo evaluate various adverse symptoms during short‐term use of ulipristal acetate in women with uterine myomas (n = 90), adenomyosis (n = 3) or both (n = 7).MethodsOne hundred premenopausal women who received ulipristal acetate for 4–12 weeks during 2016 to 2017 were selected. The medical records were reviewed and the following information was collected; adverse symptoms during medication, presence of menorrhagia or menstrual cramps, blood hemoglobin and liver function test. Adverse symptoms were recorded in the medical records as a checklist form including 76 specific progestin‐related symptoms.ResultsOverall, the most frequent adverse symptom was amenorrhea (43%), followed by weight gain (29%), fatigue (27%), abdominal discomfort (21%), decreased menstrual flow (19%) and dizziness (18%). In 89 symptomatic women (with heavy menstrual bleeding and/or menstrual cramping pain and/or anemia), the most frequent adverse symptom was weight gain (27%) and fatigue (27%), followed by abdominal discomfort (21%), dry eye (18%), facial flushing (17%), dizziness (17%), headache (17%) and increased vaginal discharge (15%). Fourteen women stopped the medication due to unwanted adverse symptoms. Of this discontinuation group, major complaint was fatigue (50%), followed by weight gain (36%) and breast discomfort (35.7%).ConclusionAdverse symptoms were common and discontinuation rate was somewhat higher during short‐term course of ulipristal acetate. Information about incidence of various adverse symptoms should be given to women who willing to take ulipristal acetate.
